Outcomes with trastuzumab deruxtecan by biomarker status, line of treatment and prior receipt of sacituzumab govitecan in a large real-world database of patients with metastatic breast cancer.
Saved in:
| Title: | Outcomes with trastuzumab deruxtecan by biomarker status, line of treatment and prior receipt of sacituzumab govitecan in a large real-world database of patients with metastatic breast cancer. |
|---|---|
| Authors: | Tarantino P; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, USA; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, USA; Harvard Medical School, Boston, USA; Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy., Lee D; Yale School of Medicine, New Haven, USA., Foldi J; University of Pittsburgh School of Medicine, Pittsburgh, USA., Soulos PR; Yale School of Medicine, New Haven, USA., Gross CP; Yale School of Medicine, New Haven, USA., Grinda T; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, USA; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, USA; Harvard Medical School, Boston, USA., Winer EP; Yale School of Medicine, New Haven, USA; Yale Cancer Center, Smilow Cancer Hospital, New Haven, USA., Lin NU; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, USA; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, USA; Harvard Medical School, Boston, USA., Krop IE; Yale School of Medicine, New Haven, USA; Yale Cancer Center, Smilow Cancer Hospital, New Haven, USA., Tolaney SM; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, USA; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, USA; Harvard Medical School, Boston, USA., Lustberg M; Yale School of Medicine, New Haven, USA; Yale Cancer Center, Smilow Cancer Hospital, New Haven, USA., Sammons S; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, USA; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, USA; Harvard Medical School, Boston, USA. Electronic address: Sarahl_Sammons@dfci.harvard.edu. |
| Source: | ESMO open [ESMO Open] 2025 Jul; Vol. 10 (7), pp. 105330. Date of Electronic Publication: 2025 Jun 18. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Elsevier Country of Publication: England NLM ID: 101690685 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2059-7029 (Electronic) Linking ISSN: 20597029 NLM ISO Abbreviation: ESMO Open Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
